Merck's KEYTRUDA Receives FDA Approval for Bladder Cancer Treatment
Merck & Co Inc has announced that its PD-1 inhibitor KEYTRUDA has received FDA approval for treating muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy. This approval is a significant milestone for the company, as it marks the first application of KEYTRUDA in this patient population.
The approval is based on data from the KEYNOTE-905 trial, which demonstrated a 60% reduction in event-free survival risk and a 50% improvement in overall survival for patients receiving the combination treatment compared to surgery alone. This breakthrough offers hope to a patient group that has long lacked new treatment options and could influence future treatment guidelines.
Investors reacted positively to the news, contributing to a +3.03% increase in Merck's stock price, which has reached a 20-day high. This upward movement comes amid a broader market context where major benchmarks are trading sideways with mixed signals, highlighting the significance of Merck's development in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Analyst Views on MRK
About MRK
About the author
Health Canada Greenlights Subcutaneous Keytruda SC™ (Pembrolizumab) for Various Cancer Treatments
Health Canada Approval: Health Canada has approved Keytruda (pembrolizumab) as a subcutaneous formulation for multiple cancer indications.
Treatment Options: This approval expands treatment options for patients with various types of cancer, enhancing accessibility and convenience in administration.
Mubadala Investment Co PJSC Reduces ARM Holdings PLC Share Stake by 8.3% to 1.4 Million Sponsored ADS, According to SEC Filing
- Investment Stake Reduction: Mubadala Investment Company has cut its share stake in Arm Holdings by 8.3%, reducing its ownership to 1.4 million shares.
- Sponsored Ads Impact: The reduction in stake is highlighted in a recent SEC filing, indicating potential implications for sponsored ads and investment strategies.
Mubadala Investment Co PJSC Reduces Stake in Adobe Inc by 49.0% to 11,570 Shares, According to SEC Filing
- Investment Stake: Mubadala has cut its share stake in Adobe by 49.0%, reducing its holdings to 11,570 shares.
- Regulatory Filing: The reduction in shares was disclosed in a recent SEC filing.
Mubadala Investment Co PJSC Increases Stake in CVS Health Corp by 17.3% to 149,769 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its stake in CVS Health Corporation by 17.3%.
Share Count: The new total of shares held by Mubadala in CVS Health is now 149,769 shares.
Mubadala Investment Co PJSC Increases Shareholding in Gilead Sciences Inc by 30.4% to 100,178 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its share stake in ILEAD Sciences by 30.4%.
New Share Count: Following the investment, Mubadala now holds a total of 100,178 shares in ILEAD Sciences.
Mubadala Investment Co PJSC Increases Shareholding in Bristol-Myers Squibb Co by 41.3% to 256,633 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its share stake in Bristol-Myers Squibb by 41.3%.
New Share Count: The total number of shares held by Mubadala in Bristol-Myers Squibb now stands at 256,633 shares.
Health Canada Greenlights Subcutaneous Keytruda SC™ (Pembrolizumab) for Various Cancer Treatments
Health Canada Approval: Health Canada has approved Keytruda (pembrolizumab) as a subcutaneous formulation for multiple cancer indications.
Treatment Options: This approval expands treatment options for patients with various types of cancer, enhancing accessibility and convenience in administration.
Mubadala Investment Co PJSC Reduces ARM Holdings PLC Share Stake by 8.3% to 1.4 Million Sponsored ADS, According to SEC Filing
- Investment Stake Reduction: Mubadala Investment Company has cut its share stake in Arm Holdings by 8.3%, reducing its ownership to 1.4 million shares.
- Sponsored Ads Impact: The reduction in stake is highlighted in a recent SEC filing, indicating potential implications for sponsored ads and investment strategies.
Mubadala Investment Co PJSC Reduces Stake in Adobe Inc by 49.0% to 11,570 Shares, According to SEC Filing
- Investment Stake: Mubadala has cut its share stake in Adobe by 49.0%, reducing its holdings to 11,570 shares.
- Regulatory Filing: The reduction in shares was disclosed in a recent SEC filing.
Mubadala Investment Co PJSC Increases Stake in CVS Health Corp by 17.3% to 149,769 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its stake in CVS Health Corporation by 17.3%.
Share Count: The new total of shares held by Mubadala in CVS Health is now 149,769 shares.
Mubadala Investment Co PJSC Increases Shareholding in Gilead Sciences Inc by 30.4% to 100,178 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its share stake in ILEAD Sciences by 30.4%.
New Share Count: Following the investment, Mubadala now holds a total of 100,178 shares in ILEAD Sciences.
Mubadala Investment Co PJSC Increases Shareholding in Bristol-Myers Squibb Co by 41.3% to 256,633 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its share stake in Bristol-Myers Squibb by 41.3%.
New Share Count: The total number of shares held by Mubadala in Bristol-Myers Squibb now stands at 256,633 shares.
